Up to date, growing evidences have validated that the PTEN/AKT/mTOR axis are universally activated in numerous cancers including PCa, and inhibitors of these core genes are displaying great promise as the latent anticancer agents [32], [33], [34]. The gene discussed is MTOR; the disease is posterior cortical atrophy.